AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01575106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat pain applied using TSA or CHEPS
Description: TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
Study NCT00932204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)
Description: For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
Study NCT00932204 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)
Description: For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
Study NCT04229433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285 tablet
Description: Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.
Study NCT04229433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
Study NCT03228472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive brain stimulation
Description: TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes.
Study NCT03228472 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Description: Placebo treatment
Study NCT00657813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNI-330 as a brain SPECT tracer of Beta-Amyloid
Description: Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
Study NCT02889406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Description: motivational interviewing schema
Study NCT01102348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP-uP Protocol
Description: Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
Study NCT04146779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Video
Description: A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.
Study NCT04146779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posture and Strengthening Video
Description: The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.
Study NCT04146779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Video
Description: The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes
Study NCT04146779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Work Video
Description: The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.
Study NCT04146779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction Survey
Description: Participants will complete a questionnaire addressing satisfaction with the yoga program.
Study NCT04146779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Yoga Session
Description: Instructor guided yoga session twice a week
Study NCT04146779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Yoga Instructions
Description: Introduction to Yoga and Yoga poses
Study NCT04203745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonablative Fractional Diode Laser
Description: The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.
Study NCT05560256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary/Journal
Description: Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
Study NCT01764542 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy and biopsy
Description: Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
Study NCT03649282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC
Description: HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
Study NCT03384862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
Study NCT03649282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCPAP
Description: NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.
Study NCT00616915 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Wellbutrin XL
Description: Wellbutrin XL 300mg daily
Study NCT00003765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Study NCT00003765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00478933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator, Dual Chamber ; Implantable
Description: Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
Study NCT00478933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling
Study NCT02865018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine
Study NCT01456650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening.
Study NCT01520311 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: eSVS Mesh
Description: Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
Study NCT03495089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dermal electrochemical conductance (DEC)
Description: The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)
Study NCT03495089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monofilament testing
Description: Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
Study NCT03241901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine Tab 20-120mg
Description: Artemether-Lumefantrine Tablet 20-120mg
Study NCT03241901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine Tab 20-120mg
Description: Artemether-Lumefantrine Tablet 20-120mg
Study NCT03241901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Phosphate 0.25 mg/kg
Description: Primaquine Phosphate 0.25 mg/kg
Study NCT03241901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Aqueous solution prepared to mimic the taste of the intervention drug.
Study NCT04139213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone oral product
Description: To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
Study NCT04139213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone oral product
Description: To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
Study NCT04139213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable naltrexone
Description: To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
Study NCT04139213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable naltrexone
Description: To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
Study NCT04139213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy maintenance addiction care
Description: Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
Study NCT04139213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral naltrexone
Description: To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
Study NCT04353284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
Study NCT04353284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally, 4 times daily, for 7 days.
Study NCT01482585 — intervention group
Intervention type: OTHER
Intervention: CT, PET, copy number alteration
Description: Duel-energy CT, PET, copy number alteration
Study NCT03073668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior pericardiotomy
Description: The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.
Study NCT03073668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
Study NCT03677596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin-dose level 2
Description: Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
Study NCT03677596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotuzumab ozogamicin-dose level 1
Description: Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
Study NCT00768326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks
Study NCT00768326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks
Study NCT00768326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks
Study NCT00768326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks
Study NCT00768326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks
Study NCT00768326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks
Study NCT05568108 — intervention group
Intervention type: PROCEDURE
Intervention: masseteric nerve to central branch facial nerve
Description: masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
Study NCT05568108 — intervention group
Intervention type: PROCEDURE
Intervention: Masseteric nerve to free functioning muscle transfer
Description: Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
Study NCT02539420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP treatment
Description: Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
Study NCT01735279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
Study NCT01735279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
Study NCT00674583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' meningococcal vaccine GSK134612
Description: Intramuscular administration, 1 dose
Study NCT00674583 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: Intramuscular administration, 1 dose
Study NCT00122681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Intramuscular injection, 3 doses
Study NCT00122681 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™-based investigational formulation
Description: Intramuscular injection, 3 doses
Study NCT00897806 — intervention group
Intervention type: GENETIC
Intervention: Microarray analysis
Study NCT00897806 — intervention group
Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Study NCT02879227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
Study NCT02879227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
Study NCT02472041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reanimator group
Description: Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
Study NCT02472041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
Study NCT01053299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open, prospective cohort-study
Description: Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
Study NCT04701385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
Study NCT02689284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab 10 mg/kg
Description: Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
Study NCT02689284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab 15 mg
Description: Margetuximab treatment is administered IV once every 21-day cycle
Study NCT02689284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab treatment is administered IV once every 21-day cycle
Study NCT01621230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural Bupivacaine plus fentanyl
Description: The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
Study NCT01621230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural fentanyl
Description: The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
Study NCT03260634 — intervention group
Intervention type: DRUG
Intervention: Voriconazole
Study NCT01154244 — intervention group
Intervention type: OTHER
Intervention: HOMA-IR
Description: Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
Study NCT03079206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: food challenge with hazelnut